Working together to deliver cell and gene therapies for people impacted by serious diseases Learn More Our inspiration Learn More Pipeline Explore R&D EB-101 In Phase 3 development. Autologous gene-corrected cell therapy for patients with RDEB. Learn More ABO-50X Exploring the potential of ABO-50X for the treatment of genetic eye disorders. Learn More Latest News Sep 26, 2023 Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa View Press Release Sep 12, 2023 Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer View Press Release Sep 7, 2023 Abeona Therapeutics Announces Participation in Upcoming Investor Conferences View Press Release View All Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More
